PuSH - Publikationsserver des Helmholtz Zentrums München

Raghu, G.* ; Million-Rousseau, R.* ; Morganti, A.* ; Perchenet, L.* ; Behr, J. ; MUSIC Study Group

Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial.

Eur. Respir. J. 42, 1622-1632 (2013)
Verlagsversion DOI
Free by publisher
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis. Eligible subjects were adults with idiopathic pulmonary fibrosis of <3 years duration and a histological pattern of usual interstitial pneumonia on surgical lung biopsy. The primary objective was to demonstrate that macitentan (10 mg once daily) positively affected forced vital capacity versus placebo. Using a centralised system, 178 subjects were randomised (2:1) to macitentan (n=119) or placebo (n=59). The median change from baseline up to month 12 in forced vital capacity was -0.20 L in the macitentan arm and -0.20 L in the placebo arm. Overall, no differences between treatments were observed in pulmonary function tests or time to disease worsening or death. Median exposures to macitentan and placebo were 14.5 months and 15.0 months, respectively. Alanine and/or aspartate aminotransferase elevations over three times upper limit of normal arose in 3.4% of macitentan-treated subjects and 5.1% of placebo recipients. In conclusion, the primary objective was not met. Long-term exposure to macitentan was well tolerated with a similar, low incidence of elevated hepatic aminotransferases in each treatment group.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Placebo-controlled Trial; Arterial-hypertension; Interstitial Pneumonia; Ambrisentan Therapy; Vital Capacity; Pirfenidone; Bosentan; Endothelin; Efficacy; Dyspnea
ISSN (print) / ISBN 0903-1936
e-ISSN 1399-3003
Zeitschrift European Respiratory Journal
Quellenangaben Band: 42, Heft: 6, Seiten: 1622-1632 Artikelnummer: , Supplement: ,
Verlag European Respiratory Society
Verlagsort Sheffield
Begutachtungsstatus